Description: Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Home Page: zentalis.com
ZNTL Technical Analysis
1359 Broadway
New York,
NY
10018
United States
Phone:
212 433 3791
Officers
| Name | Title |
|---|---|
| Dr. Kimberly Lynn Blackwell M.D. | CEO & Director |
| Mr. Cameron S. Gallagher M.B.A. | Co-Founder, Pres & Director |
| Dr. Kevin D. Bunker Ph.D. | Co-Founder & Chief Scientific Officer |
| Ms. Melissa B. Epperly M.B.A. | CFO & Treasurer |
| Adam Levy | Sr. VP of Investor Relations |
| Ms. Andrea Paul J.D. | Gen. Counsel & Corp. Sec. |
| Dr. Meena Rao Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance |
| Dr. Carrie Brownstein M.D. | Chief Medical Officer |
| Dr. Mark Lackner Ph.D. | Chief Translational Officer & Head of Biomarker Strategy |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.661 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-04-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 177 |